Over the last 2 years, there is an extreme use of low-dose aspirin for the primary prevention of atherosclerotic cardiovascular disease. This has basically become one of the most debated topics in cardiology. Initial trials were conducted in order to suggest some of the significant benefits which would be accrued when an attempt is made to expand the use of stains and decline ASCVD rates, especially in the western countries wherein this is used for more than 45 percent of the times. There were three trials and then, they were published in 2018 and since then, no attempt was made to contract this risk especially for those people who were elderly and were aged beyond 74 years. This highlights that in the population of 875 people, nearly 78 percent were elderly people and hence, amongst them nearly 74 percent were vulnerable to get contacted with this disease and therefore , this was likely to be detrimental to the treatment at the end. The medicine of aspirin was very much helpful in promoting this and hence, at the same time an attempt was made to regulate the usage in the limit of 78.2 mg/lbs.

Ref art: https://jamanetwork.com/journals/jamacardiology/article-abstract/2772383